PDS Biotechnology Corporation (PDSB) concluded trading on Wednesday at a closing price of $1.61, with 0.4 million shares of worth about $0.64 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -12.50% during that period and on June 18, 2025 the price saw a loss of about -0.62%. Currently the company’s common shares owned by public are about 45.45M shares, out of which, 43.98M shares are available for trading.
Stock saw a price change of -8.00% in past 5 days and over the past one month there was a price change of 10.27%. Year-to-date (YTD), PDSB shares are showing a performance of -1.23% which decreased to -42.19% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.85 but also hit the highest price of $4.42 during that period. The average intraday trading volume for PDS Biotechnology Corporation shares is 475.21K. The stock is currently trading 1.13% above its 20-day simple moving average (SMA20), while that difference is up 17.47% for SMA50 and it goes to -18.28% lower than SMA200.
PDS Biotechnology Corporation (NASDAQ: PDSB) currently have 45.45M outstanding shares and institutions hold larger chunk of about 18.00% of that.
The stock has a current market capitalization of $73.59M and its 3Y-monthly beta is at 1.24. It has posted earnings per share of -$0.94 in the same period. It has Quick Ratio of 2.33 while making debt-to-equity ratio of 0.85. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for PDSB, volatility over the week remained 4.80% while standing at 5.04% over the month.
Analysts are in expectations that PDS Biotechnology Corporation (PDSB) stock would likely to be making an EPS of -0.23 in the current quarter, while forecast for next quarter EPS is -0.22 and it is -0.86 for next year. For the current quarter EPS, analysts have given the company a lowest target -0.25 which is -0.22 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -0.23 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 13.59% while it is estimated to increase by 3.00% in next year. EPS is likely to shrink at an annualized rate of 5.96% for next 5-years, compared to annual growth of 6.42% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by B. Riley Securities on November 01, 2022 offering a Buy rating for the stock and assigned a target price of $10 to it. Coverage by Cantor Fitzgerald stated PDS Biotechnology Corporation (PDSB) stock as an Overweight in their note to investors on June 28, 2021, suggesting a price target of $25 for the stock. On November 10, 2020, H.C. Wainwright Upgrade their recommendations, while on May 27, 2020, Alliance Global Partners Initiated their ratings for the stock with a price target of $4. Stock get an Outperform rating from Noble Capital Markets on March 09, 2020.
